| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg | |||
| Other Sizes |
| Targets |
Yakuchinone A inhibits the expression of cyclooxygenase-2 (COX-2), inducible nitric oxide synthase (iNOS), and tumor necrosis factor (TNF)-α mRNA in mouse skin. It also inhibits the activation of NF-κB in mouse skin. These targets are involved in the regulation of inflammation and tumor promotion, contributing to the compound's anti-inflammatory and antitumor activities.
|
|---|---|
| ln Vitro |
Yakuchinone A had IC50 values of 14.75, 31.73, 21.71, 26.07, 11.50, and 11.96 μM on A375P, B16F1, B16F10, A549, MCF-7, and HT-29 cell lines, respectively [1]. 16 h) has the ability to decrease the production of IL-17 in EL4 (mouse cell line) cells in a quantitatively-dependent way, with an IC50 value of 11.5 μM [2].
Yakuchinone A demonstrates anti-inflammatory activity by inhibiting the expression of COX-2, iNOS, and TNF-α. It also inhibits the activation of NF-κB. The compound exhibits antitumor activity in mouse skin tumor promotion models. It has antibacterial and gastric protective activities. The compound also shows antioxidant, anti-adipocyte differentiation, and anthelmintic activities. |
| ln Vivo |
In the autoimmune encephalitis (EAE) model, yakuchinone A (50 mg/kg, ip, daily, 14 days) can reduce the EAE symptoms [1].
Yakuchinone A has been studied in various in vivo models. In mouse skin, it inhibits tumor promotion induced by phorbol esters. It also inhibits the phorbol ester-induced expression of COX-2, iNOS, and activation of NF-κB. The compound has been evaluated for its effects on Anisakis simplex and Hymenolepis nana. A validated LC-MS/MS method has been used to measure yakuchinone A in plasma in pharmacokinetic studies in rats. |
| Enzyme Assay |
The in vitro assay for yakuchinone A typically involves measuring its effects on enzyme activity or receptor binding using standard biochemical techniques. The compound may be tested for its ability to inhibit COX-2, iNOS, or other enzymes. The IC50 value is determined from the dose-response curve. The compound's antioxidant activity can be assessed using DPPH or other radical scavenging assays.
|
| Cell Assay |
The in vitro cellular assay for yakuchinone A typically involves culturing relevant cell lines (e.g., macrophages, cancer cells) and treating them with varying concentrations of the compound. Cellular responses such as inflammatory cytokine secretion, cell viability, and apoptosis are measured. The compound's effects on signaling pathways such as NF-κB are assessed using Western blotting or reporter gene assays.
|
| Animal Protocol |
Animal/Disease Models: Female C57BL/6 mice [1] ]
Doses: 50 mg/kg Route of Administration: intraperitoneal (ip) injection, daily, 14 days Experimental Results: EAE scores were Dramatically diminished from the 9th to the 15th day after the onset of EAE. In vivo animal studies for yakuchinone A typically involve the use of mouse models of skin tumor promotion or inflammation. Mice are administered the compound via topical application or oral gavage. Parameters such as tumor incidence, inflammatory markers, and histopathology are assessed. Pharmacokinetic studies in rats have been performed using LC-MS/MS to measure plasma concentrations. |
| ADME/Pharmacokinetics |
Yakuchinone A has a molecular weight of 312.41 g/mol and a molecular formula of C20H24O3. It is a liquid at room temperature and should be stored refrigerated (0-10°C). The compound has a boiling point of 214 °C/2 mmHg and a flash point of 174 °C. It is soluble in chloroform, dichloromethane, ethyl acetate, DMSO, and acetone.
|
| Toxicity/Toxicokinetics |
Specific toxicology data for yakuchinone A are not extensively reported in the public domain. The compound is intended for research use only and should be handled with appropriate laboratory safety precautions. Standard safety assessments would be required before any clinical application. Researchers should consult the safety data sheet for detailed handling and disposal information.
|
| References |
|
| Additional Infomation |
1-(4'-hydroxy-3'-methoxyphenyl)-7-phenyl-3-heptanone is a ketone compound in which the heptan-3-one molecule is substituted at position 1 with 4-hydroxy-3-methoxyphenyl and at position 7 with a phenyl group. This compound, isolated from Alpinia oxyphylla, possesses antitumor activity and inhibits the activity of COX-1, COX-2, and NO synthases. It can function as a metabolite, an inhibitor of cyclooxygenase 1, an inhibitor of cyclooxygenase 2, an EC 1.14.13.39 (nitric oxide synthase) inhibitor, and an antitumor drug. It is a monomethoxyphenyl compound, belonging to the phenolic and ketone classes.
Medicinal ketone A has been reported in Alpinia oxyphylla. Yakuchinone A is a major constituent of the traditional medicine Alpinia oxyphylla and exhibits anti-inflammatory, antitumor, antibacterial, and gastric protective activities. It is also known as 1-(4-Hydroxy-3-methoxyphenyl)-7-phenyl-3-heptanone. The compound has been studied for its effects on COX-2, iNOS, and NF-κB. It has not yet entered clinical trials and is strictly for preclinical research purposes. The purity is typically >98%. |
| Molecular Formula |
C20H24O3
|
|---|---|
| Molecular Weight |
312.40276
|
| Exact Mass |
312.173
|
| Elemental Analysis |
C, 76.89; H, 7.74; O, 15.36
|
| CAS # |
78954-23-1
|
| PubChem CID |
133145
|
| Appearance |
Colorless to off-white liquid
|
| Density |
1.095g/cm3
|
| Boiling Point |
495.8ºC at 760 mmHg
|
| Flash Point |
174.3ºC
|
| Index of Refraction |
1.559
|
| LogP |
4.315
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
9
|
| Heavy Atom Count |
23
|
| Complexity |
336
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O=C(CCCCC1C=CC=CC=1)CCC1C=C(OC)C(O)=CC=1
|
| InChi Key |
TXELARZTKDBEKS-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C20H24O3/c1-23-20-15-17(12-14-19(20)22)11-13-18(21)10-6-5-9-16-7-3-2-4-8-16/h2-4,7-8,12,14-15,22H,5-6,9-11,13H2,1H3
|
| Chemical Name |
1-(4-hydroxy-3-methoxyphenyl)-7-phenylheptan-3-one
|
| Synonyms |
Yakuchinone-A
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~320.10 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (8.00 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (8.00 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (8.00 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.2010 mL | 16.0051 mL | 32.0102 mL | |
| 5 mM | 0.6402 mL | 3.2010 mL | 6.4020 mL | |
| 10 mM | 0.3201 mL | 1.6005 mL | 3.2010 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
